Caitong International Asset Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Caitong International Asset Management’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$146K	Buy	9,984 +9,869	+8,582%	+$157K	0.03%	462
2025 Q4	$886	Buy	+115	New	+$907	﹤0.01%	1389
2025 Q3	–	Sell	-2,032	Closed	-$8.13K	–	2045
2025 Q2	$8.13K	Buy	2,032 +1,745	+608%	+$6.35K	0.01%	811
2025 Q1	$913	Buy	287 +267	+1,335%	+$1.26K	﹤0.01%	1594
2024 Q4	$107	Buy	+20	New	+$149	﹤0.01%	1614

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Caitong International Asset Management's CRVS Position: Q1 2026 in Review

Caitong International Asset Management increased its Corvus Pharmaceuticals (CRVS) stake by 8,582% in Q1 2026, buying an estimated $157K and bringing the position to 9,984 shares worth $146K. The position accounts for 0.03% of the portfolio, ranked #462.

Caitong International Asset Management first reported a position in CRVS in Q4 2024 and has held it in 5 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

Caitong International Asset Management held 9,984 shares of Corvus Pharmaceuticals worth $146K as of Q1 2026.
Caitong International Asset Management bought 9,869 Corvus Pharmaceuticals shares in Q1 2026, an estimated $157K.
Corvus Pharmaceuticals made up 0.03% of Caitong International Asset Management's portfolio in Q1 2026, its #462 holding.
Caitong International Asset Management first reported a position in Corvus Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.